Calcitonin Gene Related Peptide - Drugs In Development, 2021

July 2021 | 99 pages | ID: C0A31F595791EN
Global Markets Direct

Abstracts

Calcitonin Gene Related Peptide - Drugs In Development, 2021

SUMMARY

Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Calcitonin Gene Related Peptide - Drugs In Development, 2021, outlays comprehensive information on the Calcitonin Gene Related Peptide (CGRP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Calcitonin Gene Related Peptide (CGRP) - Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and contribute to the regeneration of nervous tissue after injury. CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and linked to the transmission of pain. CGRP also plays an important role in cardiovascular homeostasis and nociception. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Preclinical and Discovery stages are 1, 1, 1, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology and Undisclosed which include indications Migraine, Cluster Headache Syndrome (Cluster Headache), Dental Pain (Toothache/Tooth Pain), Fibromyalgia (Fibromyalgia Syndrome), Inflammatory Pain, Medullary Thyroid Cancer, Osteoarthritis Pain, Pain, Psoriasis and Unspecified.

Furthermore, this report also reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)
• The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
• The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide (CGRP) - Overview
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
AfaSci Inc
Aptarion Biotech AG
Eli Lilly and Co
H. Lundbeck AS
Kissei Pharmaceutical Co Ltd
Nepsone ehf
Pharmnovo AB
Serometrix LLC
Teva Pharmaceutical Industries Ltd
Vaxxinity Inc
Calcitonin Gene Related Peptide (CGRP) - Drug Profiles
AFAP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eptinezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fremanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galcanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit CGRP for Medullary Thyroid Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KCZ-1279 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOXL-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Psoriasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UB-313 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide (CGRP) - Dormant Products
Calcitonin Gene Related Peptide (CGRP) - Discontinued Products
Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones
Featured News & Press Releases
Jun 23, 2021: Teva announces Ministry of Health, Labour and Welfare approves AJOVY (fremanezumab) Injection in Japan for the preventive treatment of Migraine in Adults
Jun 21, 2021: New data supporting the safety and efficacy profile of AJOVY (fremanezumab) shared at 7th European Academy of Neurology Congress
Jun 16, 2021: Lilly plans head-to-head study of Emgality to prevent migraine
Jun 16, 2021: Lilly plans head-to-head study of Emgality to prevent migraine
Jun 15, 2021: The Journal of the American Medical Association publishes data on efficacy and safety of preventive migraine treatment VYEPTI (eptinezumab-jjmr) when administered during an active migraine attack
Jun 03, 2021: Teva to present latest data on AJOVY (fremanezumab-vfrm) Injection at the 2021 American Headache Society (AHS) Annual Meeting, showcasing Teva’s longstanding heritage in the management of Migraine
Jun 03, 2021: Lilly reveals real-world evidence data of Emgality at AHS 2021
Jun 03, 2021: New Clinical and Real-World Data evaluating efficacy of AJOVY (fremanezumab-vfrm) Injection presented at 2021 American Headache Society (AHS) Annual Meeting
Jun 03, 2021: Lundbeck to showcase new VYEPTI (eptinezumab-jjmr) data at 63rd Annual Scientific Meeting of the American Headache Society (AHS)
Apr 19, 2021: New data presented at 2021 American Academy of Neurology (AAN) Annual Meeting Shows VYEPTI (eptinezumab-jjmr) demonstrated earlier time to freedom from headache pain and absence of most bothersome symptoms compared to placebo
Apr 19, 2021: New clinical and real-world data evaluating efficacy of AJOVY (fremanezumab-vfrm) injection and reduction of migraine burden presented at 2021 American Academy of Neurology Virtual Annual Meeting
Apr 15, 2021: Teva to present new analyses of AJOVY (fremanezumab-vfrm) Injection at Upcoming 2021 American Academy of Neurology Virtual Annual Meeting, highlighting Teva’s ongoing commitment to neurology
Apr 08, 2021: Teva Canada announces new autoinjector for AJOVY for the preventive treatment of migraine in adults
Feb 26, 2021: New study published in Cephalalgia identifies mechanistic differences among CGRP migraine treatments
Feb 25, 2021: Emgality (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AfaSci Inc, 2021
Pipeline by Aptarion Biotech AG, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by H. Lundbeck AS, 2021
Pipeline by Kissei Pharmaceutical Co Ltd, 2021
Pipeline by Nepsone ehf, 2021
Pipeline by Pharmnovo AB, 2021
Pipeline by Serometrix LLC, 2021
Pipeline by Teva Pharmaceutical Industries Ltd, 2021
Pipeline by Vaxxinity Inc, 2021
Dormant Projects, 2021
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021